|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
3/2/2012 8:20:29 AM
Who needs those pesky scientists? At least those who work at big pharma? After all, the best ones want to work at smaller biotechs, right? And those left behind have no idea how to innovate. Says who? Chris Viehbacher, that’s who. The Sanofi ceo let loose at the CED Life Sciences Conference this week, MedCity News reports, and was not shy about saying what he thinks. Asked about investing in internal R&D versus smaller biotechs, Viehbacher quickly acknowledged the philosophy behind recent moves to cut R&D costs, which are being slashed by 12 percent from 2008 levels to about $1.1 billion, excluding Genzyme, which Sanofi purchased last year. Those leafy R&D enclaves, though, are prime targets.
|
|
|
|
|
|
|
|
|
|
|